4.7 Article

Development of a First-in-Class Small-Molecule Inhibitor of the C-Terminal Hsp90 Dimerization

Journal

ACS CENTRAL SCIENCE
Volume 8, Issue 5, Pages 636-655

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acscentsci.2c00013

Keywords

-

Funding

  1. Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [270650915, GRK 2158: TP4a, TP4b, TP2c, TP 2d]
  2. Forschungskommission
  3. HHU Dusseldorf
  4. KinderKrebsForschung e.V.
  5. TransOnc priority program of the German Cancer Aid [70112951]
  6. ERC [Stg 85222 PreventALL, ERA PerMED 2018]
  7. Strategischer Forschungsfonds of HHU - DFG [417919780, INST 208/761-1 FUGG]
  8. John von Neumann Institute for Computing (NIC) [HKF7]
  9. Katharina-Hardt Foundation

Ask authors/readers for more resources

Heat shock proteins 90 (Hsp90) are promising therapeutic targets for cancer treatment due to their involvement in stabilizing oncoproteins. Most Hsp90 inhibitors target the N-terminal domain, but modulators that interfere with the C-terminal domain have shown potential without inducing adverse effects. A first-in-class small-molecule inhibitor targeting Hsp90 C-terminal domain dimerization has been developed, which reduces leukemia cells and induces apoptosis without inducing protective resistance mechanisms.
Heat shock proteins 90 (Hsp90) are promising therapeutic targets due to their involvement in stabilizing several aberrantly expressed oncoproteins. In cancerous cells, Hsp90 expression is elevated, thereby exerting antiapoptotic effects, which is essential for the malignant transformation and tumor progression. Most of the Hsp90 inhibitors (Hsp90i) under investigation target the ATP binding site in the N-terminal domain of Hsp90. However, adverse effects, induding induction of the prosurvival resistance mechanism (heat shock response or HSR) and associated dose-limiting toxicity, have so far precluded their clinical approval. In contrast, modulators that interfere with the C-terminal domain (CTD) of Hsp90 do not inflict HSR. Since the CTD dimerization of Hsp90 is essential for its chaperone activity, interfering with the dimerization process by small-molecule protein-protein interaction inhibitors is a promising strategy for anticancer drug research. We have developed a first-in-class small-molecule inhibitor (5b) targeting the Hsp90 CTD dimerization interface, based on a tripyrimidonamide scaffold through structure-based molecular design, chemical synthesis, binding mode model prediction, assessment of the biochemical affinity, and efficacy against therapy-resistant leukemia cells. 5b reduces xenotransplantation of leukemia cells in zebrafish models and induces apoptosis in BCR-ABL1(+) (T315I) tyrosine kinase inhibitor-resistant leukemia cells, without inducing HSR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available